Valuation: Cerus Corporation

Market Cap 488M 435M 399M 362M 681M 46.09B 696M 4.76B 1.91B 24.4B 1.83B 1.79B 77.28B P/E 2026 *
-74.3x
P/E 2027 * -322x
Enterprise Value 493M 439M 403M 366M 688M 46.56B 704M 4.81B 1.93B 24.65B 1.85B 1.81B 78.07B EV / Sales 2026 *
2.03x
EV / Sales 2027 * 1.8x
Free-Float
96.39%
Yield 2026 *
-
Yield 2027 * -
1 day+3.21%
1 week-0.21%
Current month+5.92%
1 month+5.92%
3 months+10.27%
6 months-11.21%
Current year+17.23%
1 week 2.11
Extreme 2.11
2.52
1 month 2.11
Extreme 2.11
2.52
Current year 1.62
Extreme 1.62
3.47
1 year 1.38
Extreme 1.38
3.47
3 years 1.12
Extreme 1.12
3.47
5 years 1.12
Extreme 1.12
7.98
10 years 1.12
Extreme 1.12
8.87
Manager TitleAgeSince
Chief Executive Officer 51 2026-06-30
Chief Tech/Sci/R&D Officer 82 2015-06-30
Director of Finance/CFO 54 2009-05-03
Director TitleAgeSince
Chairman 59 2026-03-15
Director/Board Member 72 2014-03-23
Director/Board Member 51 2026-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 Sell

General Counsel

-30,000 0.0150%
7/16/26 Sell

Chief Executive Officer

-16,666 0.0083%
7/1/26 Free

Chief Executive Officer

924,215 0.4613%
Change 5-day change 1-year change 3-year change Capi.($)
+3.21%-0.21%+66.55%+39.60% 488M
+5.59%+12.54%-8.18%+20.52% 200B
+6.15%+10.74%+16.08%+44.65% 128B
+9.37%+11.73%-6.33%+22.96% 129B
+0.24%+6.40%-40.06%+9.81% 97.53B
+3.96%+9.14%+2.75%+81.38% 67.55B
+5.56%+7.19%+16.84%-19.20% 56.98B
+3.94%+24.10%-3.26%+62.72% 55.04B
-1.39%-8.56%-2.92%+53.39% 51.24B
-1.20%+6.13%+4.21%-6.48% 37.43B
Average +3.55%+7.71%+4.57%+30.94% 82.39B
Weighted average by Cap. +4.65%+9.78%-3.99%+29.29%

Financials

2026 *2027 *
Net sales 242M 216M 198M 180M 339M 22.92B 346M 2.37B 949M 12.13B 910M 891M 38.42B 264M 235M 216M 196M 368M 24.93B 377M 2.58B 1.03B 13.19B 990M 969M 41.8B
Net income -7.3M -6.51M -5.97M -5.43M -10.2M -690M -10.43M -71.35M -28.6M -365M -27.42M -26.83M -1.16B -3.49M -3.11M -2.85M -2.59M -4.87M -330M -4.98M -34.09M -13.67M -175M -13.1M -12.82M -553M
Net Debt 5M 4.46M 4.09M 3.71M 6.98M 473M 7.14M 48.84M 19.58M 250M 18.77M 18.37M 792M -13M -11.58M -10.62M -9.65M -18.15M -1.23B -18.56M -127M -50.9M -650M -48.8M -47.75M -2.06B
Projected Income Statement - Annual - Cerus Corporation
Logo Cerus Corporation
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Employees
268
Date Price Change Volume
26-11-04 $2.415 +3.21% 2,512,557
26-11-03 $2.340 -0.85% 3,497,692
26-11-02 $2.360 +3.51% 3,984,992
26-10-30 $2.280 -6.56% 1,503,449
26-10-29 $2.440 +0.83% 1,353,264
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
MarketScreener Ratings - Cerus Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.415USD
Average target price
5.125USD
Spread / Average Target
+112.22%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cerus Corporation
  1. Stock Market
  2. Stocks
  3. CERS Stock